Cargando…
Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors
Adjuvant therapy employing cytotoxic chemotherapy, molecularly targeted agents, immunologic, and hormonal agents has shown a significant impact upon a variety of solid tumors. The principles that guide adjuvant therapy differ among various tumor types and specific modalities, but generally indicate...
Autores principales: | Kirkwood, John M., Tarhini, Ahmad, Sparano, Joseph A., Patel, Prapti, Schiller, Joan H., Vergo, Maxwell T., Benson, Al B., Tawbi, Hussein |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555872/ https://www.ncbi.nlm.nih.gov/pubmed/22520262 http://dx.doi.org/10.1016/j.ctrv.2012.03.007 |
Ejemplares similares
-
Adjuvant Therapy: Melanoma
por: Davar, Diwakar, et al.
Publicado: (2011) -
CD8+ T cell responses in metastatic melanoma patients receiving an adenovirally antigen engineered dendritic cell vaccine +/- IFN-α
por: Du, Samuel, et al.
Publicado: (2015) -
High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
por: Davar, Diwakar, et al.
Publicado: (2017) -
Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours
por: Tawbi, H A, et al.
Publicado: (2011) -
Paradigms and Controversies in the Treatment of HIV-Related Burkitt Lymphoma
por: Petrich, Adam M., et al.
Publicado: (2012)